The first monkey clones produced by method that made Dolly
Sunday, 28 January 2018
Sunday, 28 January 2018
Meet Zhong Zhong and Hua Hua
Posted by ZenMaster at Sunday, January 28, 2018
Labels: China, cloning, egg, embryo, epigenetic, ethics, fibroblast, macaque, primate, reprogramming, research, Science 0 comments
Sunday, 22 March 2015
The ISSCR Issues Statement on Human Germ Line Genome Modification
Posted by ZenMaster at Sunday, March 22, 2015
Labels: chromosomes, CRISPR, designer baby, DNA, egg, embryo, ethics, Gene Therapy, genome, hESCs, human, ISSCR, legislation, nucleus, oocyte, sperm, stem cells, TALEN 0 comments
Thursday, 29 January 2015
Mitochondrial Donation: How Many Women Could Benefit?
Posted by ZenMaster at Thursday, January 29, 2015
Labels: chimera, cloning, designer baby, egg, ethics, human, mitochondria, oocyte, research, SCNT, sequence, sperm, UK 0 comments
Tuesday, 21 October 2014
Shopping for an Egg Donor
![]() |
| Human egg cell. |
Posted by ZenMaster at Tuesday, October 21, 2014
Labels: donation, egg, embryo, ethics, human, IVF, oocyte, US 0 comments
Saturday, 4 October 2014
World's first child born after uterus transplantation
Posted by ZenMaster at Saturday, October 04, 2014
Labels: egg, enzyme, ethics, human, sperm, Sweden, uterus 0 comments
Wednesday, 6 November 2013
Human Stem Cell Research in Europe
Posted by ZenMaster at Wednesday, November 06, 2013
Labels: embryonic, ethics, EU, human, medicine, regenerative, research, stem cells 0 comments
Thursday, 12 April 2012
Exploring the Risk and Rewards of Stem Cell Products
Exploring the Risk and Rewards of Stem Cell Products
Thursday, 12 April 2012
Contact: Kim Irwin
.........
Posted by ZenMaster at Thursday, April 12, 2012
Labels: California, ethics, human, legislation, medicine, research, stem cells, US 0 comments
Thursday, 4 August 2011
ScienceLive Chat about Stem Cell Future
ScienceLive Chat about Stem Cell Future
Thursday, 04 August 2011
Today, Thursday at 3 PM EDT, ScienceLive will be running a live
chat on the future of stem cell research. Our staff writer Jocelyn Kaiser,
will be moderating, and she'll have Hank Greely and Amander Clark on as science
guests.
This chat is part of a new venture for us, called ScienceLive, where we bring
our readers in touch with prominent scientists on a weekly basis so they can
ask questions on the hottest topics in science.
Follow it here:
Source: Science
Contact: Yasmin Ogale, Assistant
Producer, ScienceLive
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Thursday, August 04, 2011
Labels: embryonic, ethics, human, iPS, legislation, stem cells, US 0 comments
Thursday, 9 June 2011
Curtailing Embryonic Stem Cell Research Would also Hurt iPS Cell Research
Curtailing Embryonic Stem Cell Research Would also Hurt iPS Cell Research
Thursday, 09 June 2011
![]() |
Stanford bioethicist Christopher Scott. |
The finding strongly refutes the idea that embryonic stem cell research can be abandoned in favour of the less-controversial iPS cells, which are derived from adult human tissue.
"If federal funding stops for human embryonic stem cell research, it would have a serious negative impact on iPS cell research," said Stanford bioethicist Christopher Scott, citing a "false dichotomy" between the cell types.
"We may never be able to choose between iPS and ES cell research because we don't know which type of cell will be best for eventual therapies."
Scott, who directs Stanford's Stem Cells in Society Program, is the first author of the study, which compared the patterns of scientific publication on human embryonic and induced pluripotent stem cells. The study will be published in the June 10 issue of Cell.
The researchers also concluded that human embryonic stem cell research does not siphon federal funding away from studies of iPS cells, as has been claimed by the two plaintiffs in an ongoing Washington, D.C., district court case under consideration by Judge Royce Lamberth. Instead, studies of the two types of stem cells are likely to occur in tandem as established embryonic stem cell researchers rush to buffer themselves against a possible loss of federal funding.
"We're finding that scientific decisions are being made not because of science, but in response to other constraints, such as which cell types qualify for federal funding, how many lines are available and which can be obtained quickly and easily," said Scott.
As a result, the fields have become so tightly intertwined as to be inseparable; any loss of funding for these researchers will negatively impact all the work in their labs, including iPS cell research, Scott and his colleagues conclude.
Unlike embryonic stem cells, which are derived from human embryos, iPS cells can be created from adult tissue such as skin cells. They look and act like embryonic stem cells, but recent research has suggested that there are significant differences between the two cell types that may affect how they can be used for research and eventual human therapies.
In 2001, then-President George W. Bush restricted the use of federal funds to research on human embryonic stem cell lines derived before Aug. 9 of that year; in March 2009, President Barack Obama reversed that decision to allow research on many more cell lines. However, the legality of federal funding for human embryonic stem cell research is now being considered in the ongoing district court case filed in August 2010.
Scott and his colleagues, including senior author Jason Owen-Smith, PhD, associate professor of sociology and of organizational studies at the University of Michigan, analyzed more than 2,000 scientific papers published between 2007, when iPS cells were first reported, and 2010. They compared how many papers described research using exclusively human ES cells, human iPS cells, or both ES and iPS cells.
"It's always really interesting to look more closely at things that appear in the popular press," said Scott.
"We've been hearing that, since we now have iPS cells, we don't need to continue embryonic stem cell research. There's a perception that iPS cells are 'democratizing' the field because they are fairly straightforward to work with from a technical point of view."
The analysis of published papers tells a different story. Scott, Owen-Smith and their colleagues found that the iPS field is dominated by well-established, senior hES cell researchers. Many of these researchers are publishing studies that directly compare hES cells with iPS cells, rather than focusing exclusively on one cell type.
"Although we did see a very rapid uptake of iPS cell technology during the first three years, we didn't find many new researchers moving into the field," said Scott.
"The scientists who are adopting iPS quickly are the usual suspects. The old guard is working furiously to develop new iPS cell lines."
The researchers found that the original two papers in 2007 describing the creation of iPS cells had blossomed to 158 papers focused on iPS cells in 2010. In contrast, human embryonic stem cell technology was adopted much more slowly, from the first paper in 1999 to just 12 papers in 2001. Although the prior hES cell research made the adoption of iPS cell research easier, Scott and his colleagues attribute the difference in uptake of technologies to be primarily policy-driven, as researchers increasingly began to look for alternatives to the politically controversial hES cells.
However, stem cell scientists are not abandoning hES cells in favour of iPS cells. In 2008, only three of the 15 iPS cell papers (5 percent) published also reported hES cell results; in 2010, 98 of the 158 iPS cell papers (about 26 percent) did so.
"The incentives to use both types of cell in comparative studies are high because the science behind human iPS cells is still in its infancy," Owen-Smith said.
"As a result, induced pluripotent stem cells do not offer an easy solution to the difficult ethical questions surrounding embryonic stem cell research."
Scott and his colleagues also directly polled stem cell researchers at the 2010 annual meeting of the International Society for Stem Cell Research, which was held in San Francisco, as to their choice of cell lines, and compared patterns of collaboration in the iPS and hES cell fields. They found that, between 2008 and 2009, 55 senior authors (those listed as last authors) published papers using both hES and iPS cells. Only 14 of the senior authors published papers using iPS cells alone. The finding suggests that iPS cell technology has not been as widely disseminated as may have been expected and that senior researchers vulnerable to legislative changes affecting ES cell research continue to dominate the field.
"The deeper implications of a federal ban or restrictions on hES cell research are largely missing from the policy discussion surrounding the Lamberth decision," they write.
"We now have clear evidence showing the real possibility of collateral damage caused by ill-conceived and politically motivated policy prescriptions. Restrictions, regulatory uncertainty and spurious court decisions have undoubtedly retarded progress in the pluripotent stem cell field. Now, an entirely new technology, forged out of the crucible of political controversy, stands at risk."
Source: Stanford University Medical Center
Contact: Krista Conger
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Thursday, June 09, 2011
Labels: embryonic, ethics, hESCs, human, iPS, stem cells, US 0 comments
Tuesday, 3 May 2011
Researchers in Brazil Establish the First Line of Human Embryonic Stem Cells
Researchers in Brazil Establish the First Line of Human Embryonic Stem Cells
Tuesday, 03 May 2011
Brazilian researchers, reporting in the current issue of Cell Transplantation, discovered difficulties in establishing a genetically diverse line of human embryonic stem cells (hESC) to serve the therapeutic stem cell transplantation needs of the diverse ethnic and genetic Brazilian population.
According to the study's corresponding author, Dr. Lygia V. Pereira of the Molecular Genetics Laboratory at the University of Sao Paulo, Brazil, pluripotent human embryonic stem cells are an important tool for basic and applied stem cell transplantation research. However, immunocompatibility is an issue, especially in a genetically diverse population such as that in Brazil where the population is comprised of European, African and Native South American ancestry.
In their study, the researchers developed an hES cell line (the first in South America) they called "BR-1" derived from a Brazilian population with embryos donated by couples who had sought assistance from private fertility clinics. Their research was compatible with the 2005 Brazilian national legal, ethical and clinical guidelines for embryonic stem cell research using tissue that had been frozen for the legally mandated time of at least three years, and that had been produced for reproductive reasons.
Their results showed that the hES cell lines they established were a "worse match" to the Brazilian population than hESC lines developed elsewhere, particularly those developed in the U.S. and Singapore.
The reasons for that may be several, said Dr. Pereira.
"The Brazilian population is one of the most heterogeneous in the world, and the genes of Brazilians are mosaics," said Dr. Pereira.
"However, an analysis of BR-1 showed that it is mostly European in origin. The reproductive assistance offered by the Brazilian public health system does not include cryopreservation of surplus embryos, meaning that the only research material available came from private clinics where couples with above-average incomes could afford the high cost of assisted reproduction."
According to the researchers, that segment of the Brazilian population is mostly composed of people self-identified as white - of European ancestry - and so is not representative of Brazilian ethnic admixture and, thus, is unable to be widely compatible with Brazil's diverse population genetics.
"Although we have successfully established the first line of hESCs from the Brazilian population that adds to the pool of genetically different pluripotent cells available, it will be important to have access to embryos from the more mixed population and assistance from the Public Health System," concluded Dr. Pereira.
"Use of embryonic stem cells (ES) in regenerative medicine is very promising, but the potential problems of tumour development, cell rejection due to histo-incompatibility, and contamination with animal products employed in the cell culture need to be overcome," said Dr. Julio Voltarelli, professor of Clinical Medicine and Clinical Immunology at the University of Sao PĂ£ulo, Brazil and section editor for Cell Transplantation.
"In this study, Dr Pereira and colleagues compared the HLA compatibility between their ESC line, the first established in Brazil, and a sample of the Brazilian population who volunteered as donors for hematopoietic stem cell transplantation (REDOME). They found few matches for the ESC line in the representative population, which was attributed to the great genetic heterogeneity of the Brazilian population. This finding may add another difficulty to the clinical use of ESC in Brazil and other mixed populations even once the safety issues of ESC lines are resolved."
Source: Florida Science Communications
Contact: Randolph Fillmore
Reference:
Establishment Of A Brazilian Line Of Human Embryonic Stem Cells In Defined Medium – Implications For Cell Therapy In An Ethnically Diverse Population
Fraga, A. M.; Sukoyan, M.; Rajan, P.; Braga, D. P. F.; Iaconelli, A., Jr.; Franco, J. G., Jr.; Borges, E., Jr.; Pereira, L. V.
Cell Transplant. 20(3):431-440; 2011.
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Tuesday, May 03, 2011
Labels: donation, embryonic, ethics, hESCs, human, research, stem cells 0 comments
Wednesday, 26 January 2011
Chinese Academy of Sciences Initiates "Trailblazing" Stem Cell Research Project
Chinese Academy of Sciences Initiates "Trailblazing" Stem Cell Research Project
Wednesday, 26 January 2011
The Chinese Academy of Sciences (CAS) on Tuesday announced it has initiated a "strategic, trailblazing" research project on stem cells and regenerative medicine.
The project mainly aims to remove the bottlenecks China is confronted with in stem cell research, the CAS said in its 2011 work meeting in Beijing.
The project will focus on the research of stem cell regulations, core mechanisms for stem cell therapies, and other key technologies, it said.
The CAS said it would establish a world-class research platform and base for stem cell and regenerative medicine research through the project.
The stem cell research project is one of eight such trailblazing projects of the CAS. The others include projects on nuclear fission, space science and clean energy.
Source: Chinese Academy of Sciences
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Wednesday, January 26, 2011
Labels: China, ethics, legislation, medicine, regenerative, research, stem cells 0 comments
Tuesday, 16 November 2010
The Next Generation of Bioethics
Pharmaceutical company bioethics? Public health bioethics? Regenerative medicine bioethics?
Tuesday, 16 November 2010
To celebrate 40 years of pioneering bioethics publication, the Hastings Center Report, the world's first bioethics journal, looked to the future, asking young scholars to write about what the next generation of bioethicists should take up. Out of 195 compelling submissions, four of the best essays were selected for publication in the November-December issue.
Three of the essays envision bioethics forging into new areas, such as the ethical obligations of pharmaceutical industry, questions around the emerging field of regenerative medicine, and public health. Another proposes broadening the approach to dying, a foundational issue of bioethics. An undergraduate, a graduate student, an early career professor who is also a practicing physician, and a Belgian researcher are the authors.
A second set of essays, focusing on bioethics methodology, will be published in 2011.
"Picking the essays we wanted to publish turned out to be surprisingly difficult," said Gregory E. Kaebnick, editor of the Report.
"We not only wanted good essays; we also wanted to represent the range of topics that people had written about and the range of people writing them up. But it's a good problem to have, of course, and it gives us great confidence about the future of bioethics."
- "Establishing a 'Duty of Care' for Pharmaceutical Companies" calls upon bioethics to focus on the ethical responsibilities that drug companies have to the people they supply. Just as doctors, nurses, and other clinicians have a duty to give competent care to patients, drug companies should "place the good of the populace over the good of the stockholders," writes Remy Miller, a junior at Transylvania University who plans to pursue degrees in medicine and bioethics. She suggests that companies start by adhering to the bioethics principles of justice, beneficence, and autonomy.
- "A Role for Moral Vision in Public Health" recommends that bioethics join forces with public health to develop a moral vision to inform policy and practice. While public health interventions were once accomplished through improvements in infrastructure, such as better sanitation, "today's public health goals often require changing individual behaviour, often through state action," writes Daniel B. Rubin, a doctoral student in public health and a law student at the University of Michigan Rubin.
"Such interventions raise substantive questions about the extent to which government . . . should intrude on individual bodies to improve the health of the body politic."
- "The Art of Dying Well" argues that one of the most pressing bioethical concerns is to create a framework for teaching an aging population to prepare for death and support one another through the dying process. Even though bioethics has always debated end-of-life issues, Lydia Dugdale, MD, an assistant professor at Yale School of Medicine, says, "American society remains ill equipped for the experience of dying." Among the reasons are advances in medical technology that have "obscured the distinction between death and life," physicians' difficulty in discussing end-of-life issues with their patients, and the secularization of Western culture, which has marginalized the role of religion in preparing people for death. Bioethics can help, Dugdale says, by working to create "a modern version of the Ars moriendi, or Art of Dying, which expressed the societal and ecclesiastical response in the Middle Ages to the widespread death caused by the plague."
- "The Challenge of Regenerative Medicine" outlines the ethical questions raised by the effort under way in all medical fields to regenerate human tissue as a means of treating degenerative diseases.
"In the future, regenerative medicine may therefore touch most of our lives," writes Leen Trommelmans, PhD, who teaches ethics and philosophy to nursing, midwifery, and facility management students at KaHO Sint-Lieven in Belgium and does research at the Centre for Biomedical Ethics and Law at Catholic University in Leuven. So far, bioethics has focused on the use of stem cells in regenerative medicine, but other questions remain unexamined, including the rights of donors whose cells are used, the availability of costly regenerative treatments to those who cannot afford them, and the prospects of using regenerative medicine for enhancement, such as the prevention of aging.
Source: The Hastings Center
Contact: Michael Turton
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Thursday, 23 September 2010
Ethical Dilemmas with the Growing Support for Personalized Medicine
Ethical Dilemmas with the Growing Support for Personalized Medicine
Thursday, 23 September 2010
As US government support for personalized medicine grows, a consumer advocate, a patient, and bioethicists explore ethical controversies. Direct-to-consumer genetic tests, privacy, targeted cancer therapies, and Henrietta Lacks are among topics in a special issue of the Hastings center Report.
Behind the high expectations raised by personalized medicine – the use of genetic information to individualize treatment, improve care, and possibly save money – a series of essays in The Hastings Center Report examines the challenges in determining what is effective; benefits and drawbacks for patients; and consumers' right to their genetic information, however imperfect. Ronni Sandroff, an editorial director of Consumer Reports, writes on controversies surrounding direct-to-consumer tests and discusses her essay in a podcast.
"The Prospects for Personalized Medicine"
A roundup of recent government initiatives to promote personalized medicine, successes with genetically customized drug treatments, and quality control problems with genetic tests is given by Shara Yurkiewicz, a first-year student at Harvard Medical School.
"Personalized Medicine's Ragged Edge"
How should we determine who should get expensive treatments? If there were a thick, bright line separating the minimal responders from the maximal responders, then we could allocate these treatments fairly. But the reality, explains Leonard Fleck, a bioethicist at Michigan State University, is more like a ragged edge – some people will clearly benefit a lot, some people will clearly not benefit at all, and many people will benefit somewhat.
"Personalized Cancer Care in an Age of Anxiety"
To get an idea of how personalized medicine could reshape patient care in the years ahead, one need only look at how it is beginning to reshape the care of patients with cancer, writes Susan Gilbert, Hastings Center staff writer, who surveys those changes.
"A Patient's Experience"
Marian Fontana, a New York author, describes her experience with genetic testing to guide her treatment for breast cancer.
"Direct-to-Consumer Genetic Tests and the Right to Know"
Ronni Sandroff, editorial director, Family and Health, of Consumer Reports, appraises the young DTC genetic testing industry in the wake of recent government investigations that exposed inaccuracies and other problems. She argues against having doctors as gatekeepers of genetic information and favours government regulation to insure that the DTC tests are reliable and are not used as marketing devices for unproven products.
"Wanted: Human Biospecimens"
For personalized medicine to realize its potential, researchers will need thousands of samples of human tissue, blood, urine, and other bio-specimens for genetic studies, writes Karen Maschke, a Hastings Center research scholar. But this need has raised many ethical issues around informed consent and privacy, rendered vividly by recent events, including lawsuits involving use of newborn screening blood samples for research, a legal settlement with the Havasupai Indian tribe over genetic research with their blood, and publication of the bestselling book on the "immortal cells" of Henrietta Lacks.
Source: The Hastings Center
Contact: Mary Crowley
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Thursday, September 23, 2010
Labels: embryonic, ethics, hESCs, human, iPS, stem cells 0 comments
Saturday, 4 September 2010
ISSCR Decries Negative Impact of Stem Cell Injunction on Science and Medicine
ISSCR Decries Negative Impact of Stem Cell Injunction on Science and Medicine
“Information on hESCs is essential so that we can discover new niches for adult stem cells in more tissues, learn how they differ from hESCs, and begin to understand how to expand the more limited capacity of adult stem cells. Without government funds to support this research, U.S.-based scientists and physicians will be impeded in developing the blueprint for stem cell therapies that will save lives.”
https://ecf.dcd.uscourts.gov/cgi-bin/show_public_doc?2009cv1575-44
NIH notification regarding applications for grants and contracts that involve human embryonic stem cells (hESCs) (Aug. 30, 2010)
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-10-126.html
Statement from NIH Director Francis Collins (Aug. 26, 2010) http://www.nih.gov/about/director/08262010statement_stemcellinjunction.htm
Justice Department Motion to Stay and Notice of Appeal (Aug. 31, 2010)
http://www.nih.gov/about/director/stemcell/appeal_08312010.pdf
http://www.nih.gov/about/director/stemcell/stay_08312010.pdf
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Saturday, September 04, 2010
Labels: embryonic, ethics, human, ISSCR, legislation, stem cells, US 0 comments
Thursday, 2 September 2010
People Want to be Asked before Sharing Genetic Data
Group Health study is first to ask patients about sharing their data
Thursday, 02 September 2010
People want to be informed and asked for consent before deciding whether to let researchers share their genetic information in a federal database. This is according to a team of investigators at Group Health Research Institute and the University of Washington (UW). The team's report, called "Glad You Asked," is in the September 2010 Journal of Empirical Research on Human Research Ethics.
To the team's knowledge, it is the first to ask research participants' opinions about the need for informed consent for sharing their own information. The team explored participants' preferences while collaborating on the Electronic Medical Records and Genomics (eMERGE) Network. The Network involves volunteers enrolled in the joint Group Health-UW Adult Changes in Thought (ACT) study. ACT is a longitudinal cohort study that tracks aging-related changes in thousands of older Group Health patients over time.
When the team asked Group Health patients who participate in ACT whether their "de-identified" (anonymous) genetic and medical record information could be shared in the database, 86 percent said yes. Then the team surveyed 365 ACT study participants who had agreed to let their genetic information be shared, mostly because of a "desire to help others." In the survey, 90 percent of participants said they thought it was important to have been asked for this reconsent.
Reconsent means getting additional informed consent from research participants before using their information for a purpose beyond what they agreed to originally. Alternatives to reconsent — including opting out, being notified, or neither individual permission nor notification — were unacceptable to 40 percent, 67 percent, and 70 percent of the surveyed participants, respectively.
![]() |
Evette J. Ludman, Ph.D.. Credit: Group Health Research Institute. |
"This indicates that even if most of a study's participants would agree to data sharing, it's still crucial to ask them."
Since 2008, the National Institutes of Health (NIH) has strongly encouraged many studies to submit genetic information to the federal database of Genotypes and Phenotypes (dbGaP). The reason is that genomic research on large numbers of people can yield insights that are not possible with smaller numbers.
For new studies that will enrol participants prospectively, informed consent can — and should — address such sharing. But sharing genetic data raises ethical questions for longitudinal cohort studies, including ACT, which started long before dbGaP was established in 2006. Few existing informed consents address data sharing through this new mechanism. Ideally, Dr. Ludman suggested, research grants would include funding and time to pursue reconsent. In this study, it cost around $50 for each participant who was asked.
"Trust is a two-way street, and human research requires lots of trust," Dr. Ludman said.
"People have an understandable feeling of ownership over their bodies and medical records, including their genetic information," she added.
"Researchers show we're worthy of trust when we ask research participants for permission to use their information in a way that they haven't already agreed to."
Recent high-profile legal cases have highlighted the issue of consent and trust in research, including the Havasupai tribe vs. Arizona State University and parents vs. the Texas health department over storing newborn blood samples without parental consent. So too has the bestselling book, “The Immortal Life of Henrietta Lacks”, about the history surrounding the HeLa cell line, the world's most widely grown human cells.
About:
The eMERGE Network:
The Electronic Medical Records and Genomics (eMERGE) Network is a national consortium formed to develop, disseminate, and apply approaches to research that combine DNA biorepositories with electronic medical record (EMR) systems for large-scale, high-throughput genetic research. The Network brings together researchers with a wide range of expertise in genomics, statistics, ethics, informatics, and clinical medicine from leading medical research institutions across the country: Group Health Cooperative with the UW; Marshfield Clinic; Mayo Clinic; Northwestern University; and Vanderbilt University.
Group Health Research Institute:
Founded in 1947, Group Health Cooperative is a Seattle-based, consumer-governed, non-profit health care system. Group Health Research Institute changed its name from Group Health Center for Health Studies on September 8, 2009. Since 1983, the Institute has conducted non-proprietary public-interest research on preventing, diagnosing, and treating major health problems. Government and private research grants provide its main funding.
UW Medicine:
The UW Medicine health system includes UW Medical Center, Harborview Medical Center, Northwest Hospital, the UW School of Medicine, UW Medicine Neighborhood Clinics, UW Physicians, Airlift Northwest, and the UW's partnership in the Seattle Cancer Care Alliance with Seattle Children's and Fred Hutchinson Cancer Research Center. UW Medicine has major academic and service affiliations with Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, and the Veterans Affairs Puget Sound Health Care System in Seattle and the VA Hospital in Boise. The UW School of Medicine is the top public institution for biomedical research in funding received from the National Institutes of Health.
Source: Group Health Research Institute
Contact: Rebecca Hughes
.........
ZenMaster
For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/
Posted by ZenMaster at Thursday, September 02, 2010




